BHI News Section

BD is a leading global medical technology company that creates medical technology, devices and laboratory equipment for a variety of needs across the healthcare continuum. At BD, we are looking for candidates who possess passion, innovative solutions and a commitment to our one mission of improving access to groundbreaking medical and biotechnology services for people near and far, delivering state-of-the-art technology and cutting-edge research in the battle to fight and cure infectious diseases. With a global reach that extends across 50 countries worldwide, our network of professionals collaborates on effective measures to deliver enhanced patient quality such as lower health care delivery costs, improved health care and safety, and expanded health care for all. Join our company and see how you can become a part of one global mission to make a difference in human health.

Dr. Murat Kalayoglu, President and CEO at Cartesian Therapeutics, provides an update since his last visit on their cell and gene therapies, as well as fundraising successes.

Listen now on Apple https://apple.co/2SuVe2M, Google https://bit.ly/35Uq6wV, Spotify https://spoti.fi/3w3d7nd, or TuneIn https://bit.ly/2U9zYjL

Delta customers now have more ways to meet COVID-19 test requirements introduced by the U.S. Centers for Disease Control and many international governments during the pandemic. Convenient and accurate in-home rapid antigen tests that can be shipped directly to a home address or picked up locally are now available for purchase on delta.com.

“Even as the U.S. achieves widespread immunity through vaccinations, many international countries lag behind the U.S. in vaccination rates. Testing and proof of a negative test result within 72 hours of travel remain core components for entry to many international destinations as well as to return to the U.S. during the global pandemic,” said Henry Ting – S.V.P. & Chief Health Officer. “These new purchase and pack COVID-19 tests offer a convenient option to provide proof of a negative test result and enable a seamless experience for our customers.”

Moderna CEO Stéphane Bancel made the decision to build his mRNA research-and-development platform on public cloud to create what he calls “software for life.”1 He used the cloud as a means to accelerate therapeutic discovery and development. When the COVID-19 pandemic hit, this strategy proved prescient. The company was well positioned to quickly design research experiments and to harness its automated laboratory and manufacturing processes and enhanced drug-discovery pipeline.

Emmes today announced that it was selected as one of the best places to work in the greater Washington area. This is the fifth time that the company has been chosen as a top workplace by The Washington Post, whose rankings are based on the highest employee engagement ratings.

The Post’s 2021 Top Workplaces list included a wide range of organizations, including government contractors, law and real estate firms, professional and business services firms, and technology companies.

The Post partnered with employee engagement firm Energage, LLC, to conduct the survey, asking employees about the companies they work for on topics ranging from employee development to innovation. More than 3,500 area companies were invited to participate, representing over 65,500 employees. Emmes was selected as a top workplace in the large company category.

Many of you are following the ongoing effort by some political leaders to strip our scientific intellectual property rights pertaining to vaccines and treatments for COVID-19. This proprietary science and technology was developed by our scientists working day and night at great financial risk to our companies.

A diverse, global team of scientists, led by University College of London and Children’s National Hospital/George Washington University, has been selected for the final stages of Cancer Grand Challenges – and is in with a chance of securing a share of £80 million (c.$111 million) of funding to take on one of cancer’s toughest problems.

Nearly 170 teams submitted ideas for this round of awards, and the NGTC team, which stands for ‘Next Generation T-cell therapies for childhood cancers, led by Martin Pule, Ph.D., University College of London, and Catherine Bollard, M.B.Ch.B., M.D., Children’s National Hospital and George Washington University, is one of 11 shortlisted groups.

It is with enormous pride and excitement that we announce that Aifred Health is #2 in the WORLD in the Global @IBM Watson AI XPRIZE!  

I could not be prouder of the entire Aifred Health team and especially the four co-Founders Robert Fratila, Kelly Perlman, Sonia Israel and David Benrimoh, MD.,CM., MSc. whose vision and passion started us on this journey. 

The US$1M prize will be used to accelerate the delivery of our AI technology in the field of #depression and to begin the work to apply our tech to other disease indications where personalize treatment choice is needed to deliver better outcomes to patients.